Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Recipient : Brand Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RELEXXII® (methylphenidate hydrochloride extended-release tablets) is an oral medication indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults up to the age of 65 and pediatric patients 6 years of age and older.
Brand Name : Relexxii
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 11, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Recipient : Brand Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Athyrium Capital Management
Deal Size : Undisclosed
Deal Type : Financing
Details : The financing provides the Company with additional cash to support the commercialization of Upneeq. As a first-in-class treatment for acquired ptosis, Upneeq offers patients and clinicians a convenient non-surgical therapeutic option.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 07, 2021
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Athyrium Capital Management
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Alora Pharmaceuticals
Deal Size : $170.0 million
Deal Type : Divestment
Details : Osmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ (Oxymetazoline Hydrochloride).
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : $110.0 million
June 25, 2021
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Alora Pharmaceuticals
Deal Size : $170.0 million
Deal Type : Divestment
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Adamas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Adamas Completes Acquisition of OSMOLEX ER®
Details : Through this acquisition, OSMOLEX ER joins the Adamas portfolio which includes GOCOVRI® extended-release capsules for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy with or without concomitant dopamin...
Brand Name : Osmolex ER
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Adamas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Adamas Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Agreement
Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas
Details : Under the terms of the agreement, both parties will drop their respective claims relating to the patent litigation, and Adamas will acquire the global rights to OSMOLEX ER for $7.5 million.
Brand Name : Osmolex ER
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 02, 2020
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Adamas Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Agreement
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis.
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Osmotica Pharmaceuticals plc is developing arbaclofen ER tablets for the treatment of spasticity in patients with MS. This program aims to demonstrate the clinical efficacy and safety of arbaclofen ER tablets in patients with spasticity due to MS.
Brand Name : AERT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : U.S FDA has approved Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, formerly known as RVL-1201, its novel treatment for acquired blepharoptosis, or ptosis, a condition characterized by the abnormal drooping of the upper eyelid that can l...
Brand Name : Upneeq
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis.
Brand Name : AERT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2020
LOOKING FOR A SUPPLIER?